In parallel, the membership of FIP has evolved to become the most extensive global pharmacy and pharmaceutical sciences network.
Professor Les Baillie, of Cardiff University's school of pharmacy and pharmaceutical sciences, said nature in Wales was a resource.
BBC: Lichen in Wales could hold key to antibiotics resistance
FIP, as the global federation bringing together pharmacists and pharmaceutical scientists, is leading in fostering pharmacy and pharmaceutical sciences education development through its various initiatives and projects.
Dr. Bloom is the director of chemical and pharmaceutical sciences at the American Council on Science and Health, a health-care education and advocacy group based in New York.
WSJ: Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?
Harvey Stenger, president of Binghamton University, then plans to recruit faculty to sharpen the school's expertise in pharmaceutical sciences and alternative energy, which he argues has the best chance to succeed as new, local industries.
The UNITWIN Network in Global Pharmacy Education Development (G-PhEd) will enable synchronised and powerful development in pharmacy and pharmaceutical sciences education by bringing together pharmacy schools from all regions of the world with UNESCO and FIP.
In addition, the G-PhEd will actively foster excellence in learning and teaching and seek to establish global centres of excellence in the field of higher education, spanning the full scope of undergraduate training and continuing pharmacy and pharmaceutical sciences education.
In bringing together pharmacy schools and faculties from all regions of the world with UNESCO and FIP, the UNITWIN Network in Global Pharmacy Education Development (G-PhED) enables synchronised and powerful development in pharmacy and pharmaceutical sciences education and improves communication for scientific innovation, healthcare outcomes, and ultimately, the attainment of the Millennium Development Goals (MDGs).
In a move that has potentially significant implications for the entire pharmaceutical industry, Gilead Sciences is challenging a crucial bit of FDA decisionmaking.
FORBES: Gilead Challenges FDA Over Exclusivity For Its Latest AIDS Drug
In June Human Genome Sciences partnered with Swiss pharmaceutical giant Novartis to jointly commercialize Albuferon in the U.S. Novartis will sell the drug outside the U.S. Of course, the risk for investors is that late-stage clinical trials could show it to be a flop.
In June Human Genome Sciences partnered with Swiss pharmaceutical giant Novartis (nyse: NVS - news - people ) to jointly commercialize Albuferon in the U.S. Novartis will sell the drug outside the U.S. Of course, the risk for investors is that late-stage clinical trials could show it to be a flop.
应用推荐